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ABSTRACT 
 
Addison's disease (AD) or primary adrenal insufficiency is a rare disease with an estimated 
prevalence of 100-140 per million inhabitants and deadly unless treated with glucocorticoids 
(GCs). Very limited information is available on the morbidity and mortality in this patient 
group. A few old studies report near normal mortality and several studies indicate impaired 
bone health and reduced health-related quality of life (HR-QoL). It has been suggested that 
GC treatment, with both too high GC doses and a replacement regime which cannot replicate 
the physiological cortisol rhythm, may partly explain the impaired outcome in AD patients. 
 
This thesis is based on studies with the main objective of studying mortality and morbidity in 
patients with AD receiving long-term GC replacement therapy. In a large nation-wide 
register-based study patients with AD had a more than two-fold higher mortality rate than the 
general population which was mainly explained by excess mortality from cardiovascular 
diseases, cancer and infectious diseases. The mortality was further increased among patients 
with AD who also had diabetes mellitus (DM).  
In a case-control study, comparing AD patients to healthy controls matched for age, gender, 
BMI and smoking habits; cardiometabolic risk factors, visceral abdominal adipose tissue 
(VAT), bone health and HR-QoL were studied. The patients did not have increased VAT 
measured using computerized tomography, but a greater proportion of patients had the 
metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). The patients had reduced 
bone mineral density (BMD) and an increased frequency of osteoporosis and osteopenia and 
patients using higher GC doses for replacement had increased risk of osteoporosis and 
osteopenia. Finally, using four different validated questionnaires we could demonstrate that 
the patients experienced more fatigue and had impaired HR-QoL. 
 
In conclusion, patients with AD in Sweden have increased mortality, which is mainly 
explained by cardiovascular diseases. Despite compatible VAT between the AD patients and 
controls, the patients have an increased prevalence of MetS and T2DM, both of which are 
known to be related to increased cardiovascular risk. Patients with AD also have impaired 
bone health and reduced HR-QoL. The thesis strongly suggests that there is a need for 
improvement in the overall management of patients with AD. 
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